Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03425526 · ClinicalTrials.gov registry record · Phase 1
Donor T Cell Therapy in Treating Immunocompromised Patients With Adenovirus-Related Disease
A Phase 1 study of Hematopoietic and Lymphoid Cell Neoplasm and Immunocompromised, sponsored by M.D. Anderson Cancer Center.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 16
- Enrollment target
- 1
- Study location
NCT03425526 is a Phase 1 study of Hematopoietic and Lymphoid Cell Neoplasm and Immunocompromised that is actively recruiting participants, run by M.D. Anderson Cancer Center. The registered enrollment target is 16 participants, below the 953-participant average among 104 other Hematopoietic and Lymphoid Cell Neoplasm trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03425526, a Phase 1 study of Hematopoietic and Lymphoid Cell Neoplasm and Immunocompromised, is actively recruiting participants, sponsored by M.D. Anderson Cancer Center.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 16 participants
- Enrollment target
- 1
- Study location
Study Summary
This phase I trial studies the side effects of allogeneic adenovirus-specific cytotoxic T lymphocytes (donor T cell therapy) and to see how well they work in treating patients with a weakened immune system (immunocompromised) and adenovirus-related disease. Allogeneic adenovirus-specific cytotoxic T lymphocytes are made from donated blood cells grown in the laboratory and are designed to kill viruses that can cause infections in immunocompromised patients with adenovirus-related disease.
Conditions Studied
Interventions
- BIOLOGICAL Allogeneic Adenovirus-specific Cytotoxic T Lymphocytes
Study Locations (1)
Texas
- M D Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2018-03-15 |
| Est. Completion | 2027-01-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03425526
The ClinicalTrials.gov registry entry for NCT03425526 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 953-participant average among 104 other Hematopoietic and Lymphoid Cell Neoplasm trials with a reported enrollment target (98% lower). The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Hematopoietic and Lymphoid Cell Neoplasm appearing as the primary indexed condition, and to 1 intervention - of which Allogeneic Adenovirus-specific Cytotoxic T Lymphocytes is the first listed.
NCT03425526 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT03425526 about?
NCT03425526 is a clinical study titled "Donor T Cell Therapy in Treating Immunocompromised Patients With Adenovirus-Related Disease". This phase I trial studies the side effects of allogeneic adenovirus-specific cytotoxic T lymphocytes (donor T cell therapy) and to see how well they work in treating patients with a weakened immune system (immunocompromised) and adenovirus-related disease. Allogeneic adenovirus-specific cytotoxic T...
What is the current status of trial NCT03425526?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2018-03-15. Estimated completion is 2027-01-01.
What conditions does trial NCT03425526 study?
This clinical trial studies the following conditions: Hematopoietic and Lymphoid Cell Neoplasm, Immunocompromised.
What interventions are being tested in trial NCT03425526?
The interventions under investigation include: Allogeneic Adenovirus-specific Cytotoxic T Lymphocytes (BIOLOGICAL).
Who is sponsoring clinical trial NCT03425526?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03425526 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hematopoietic and Lymphoid Cell Neoplasm
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer
RECRUITING · Phase 1
-
Study of Cord Blood Derived Mesenchymal Stem Cells for Treatment of Moderate, Severe or Critical Pneumonia
RECRUITING · Phase 1
-
Study Assessing the Feasibility, Safety and Efficacy of Genetically Engineered Glucocorticoid Receptor Knock Out Virus Specific CTL Lines for Viral Infections in Immunosuppressed Cancer Patients
RECRUITING · Phase 1
-
Human Lysozyme Goat Milk for the Prevention of Graft Versus Host Disease in Patients With Blood Cancer Undergoing a Donor Stem Cell Transplant
RECRUITING · Phase 1
-
Donor Bone Marrow Derived Mesenchymal Stem Cells in Controlling Heart Failure in Patients With Cardiomyopathy Caused by Anthracyclines
RECRUITING · Phase 1
-
Hu8F4 in Treating Patients With Advanced Hematologic Malignancies
ACTIVE NOT RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.